HSIC

73.04

0.90% -0.66

Handel nachbörslich: 73.04

Henry Schein Inc (HSIC)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$73.70

Offen:

$73.7

24-Stunden-Volumen:

1.15M

Relative Volume:

0.87

Marktkapitalisierung:

$8.38B

Einnahmen:

$13.18B

Nettoeinkommen (Verlust:

$419.00M

KGV:

22.33

EPS:

3.2704

Netto-Cashflow:

$521.00M

1W Leistung:

-1.63%

1M Leistung:

-11.35%

6M Leistung:

+11.34%

1J Leistung:

+5.75%

1-Tages-Spanne:

$73.00

$74.62

1-Wochen-Bereich:

$71.48

$75.59

52-Wochen-Spanne:

$60.56

$89.29

Henry Schein Inc Stock (HSIC) Company Profile

Firmenname

Henry Schein Inc

Sektor

Healthcare (1116)

Branche

Medical Distribution (11)

Telefon

(631) 843-5500

Adresse

135 DURYEA RD, MELVILLE, NY

Mitarbeiter

25,000

Twitter

@henryschein

Nächster Verdiensttermin

2026-02-24

Neueste SEC-Einreichungen

HSIC's Discussions on Twitter

Compare HSIC vs MCK, COR, CAH, AHG

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HSIC Henry Schein Inc	73.04	8.45B	13.18B	419.00M	521.00M	3.2704
MCK Mckesson Corporation	872.32	106.00B	397.96B	4.55B	9.64B	34.77
COR Cencora Inc	317.66	61.11B	325.78B	1.64B	3.61B	8.3139
CAH Cardinal Health Inc	212.02	49.72B	244.67B	1.68B	5.51B	6.9487
AHG Akso Health Group Adr	2.32	1.95B	14.85M	-136.07M	7.23M	-0.4726

Henry Schein Inc Stock (HSIC) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-23	Hochstufung	Robert W. Baird	Neutral → Outperform
2025-12-09	Eingeleitet	Barclays	Overweight
2025-08-26	Hochstufung	Evercore ISI	In-line → Outperform
2025-07-25	Herabstufung	Stifel	Buy → Hold
2025-07-14	Herabstufung	Robert W. Baird	Outperform → Neutral
2025-02-14	Eingeleitet	Wells Fargo	Equal Weight
2025-01-06	Hochstufung	BofA Securities	Underperform → Buy
2024-12-04	Eingeleitet	Mizuho	Neutral
2024-07-22	Hochstufung	Robert W. Baird	Neutral → Outperform
2024-02-26	Eingeleitet	Leerink Partners	Market Perform
2023-12-12	Hochstufung	JP Morgan	Neutral → Overweight
2023-11-10	Hochstufung	Stifel	Hold → Buy
2022-08-08	Hochstufung	UBS	Sell → Neutral
2022-07-21	Herabstufung	Goldman	Buy → Neutral
2022-06-14	Herabstufung	Robert W. Baird	Outperform → Neutral
2022-05-13	Fortgesetzt	Credit Suisse	Outperform
2022-01-31	Eingeleitet	Morgan Stanley	Underweight
2022-01-07	Hochstufung	Credit Suisse	Neutral → Outperform
2021-10-01	Fortgesetzt	Credit Suisse	Neutral
2021-02-08	Fortgesetzt	Piper Sandler	Overweight
2021-01-04	Hochstufung	Robert W. Baird	Neutral → Outperform
2020-11-03	Hochstufung	Barrington Research	Mkt Perform → Outperform
2020-05-06	Herabstufung	Barrington Research	Outperform → Mkt Perform
2020-04-07	Hochstufung	Goldman	Neutral → Buy
2020-04-02	Hochstufung	Wolfe Research	Peer Perform → Outperform
2020-01-09	Herabstufung	BofA/Merrill	Neutral → Underperform
2020-01-02	Hochstufung	Evercore ISI	Underperform → In-line
2019-08-07	Herabstufung	William Blair	Outperform → Mkt Perform
2019-05-30	Eingeleitet	Wolfe Research	Underperform
2019-05-15	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2019-04-18	Eingeleitet	Guggenheim	Buy
2019-01-17	Eingeleitet	UBS	Sell
2019-01-03	Herabstufung	Evercore ISI	In-line → Underperform
2019-01-02	Herabstufung	Robert W. Baird	Outperform → Neutral
2018-11-08	Bestätigt	Barrington Research	Outperform
2018-10-25	Herabstufung	Edward Jones	Hold → Sell
2018-10-19	Fortgesetzt	Goldman	Neutral
2018-10-04	Bestätigt	Robert W. Baird	Outperform
2018-08-07	Bestätigt	Stifel	Hold
2018-04-24	Herabstufung	Goldman	Buy → Neutral
2018-04-04	Hochstufung	Leerink Partners	Mkt Perform → Outperform

Alle ansehen

Henry Schein Inc Aktie (HSIC) Neueste Nachrichten

Mar 31, 2026

Henry Schein Inc. stock rises Tuesday, still underperforms market - MarketWatch

Mar 31, 2026

Henry Schein Inc Stock: A Steady Force in Dental and Medical Distribution for North American Investo - AD HOC NEWS

Mar 31, 2026

Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term - Yahoo Finance

Mar 31, 2026

Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Encompass Health (EHC) and Merck & Company (MRK) - The Globe and Mail

Mar 31, 2026

Mar 30, 2026

Henry Schein (HSIC) down 9.4% since last earnings report: Can it rebound? - MSN

Mar 30, 2026

Henry Schein: A Cash-Generating Healthcare Distributor Priced for Mediocrity - TradingView

Mar 30, 2026

Mar 29, 2026

Henry Schein, Inc. (NASDAQ:HSIC) Short Interest Update - MarketBeat

Mar 29, 2026

Assenagon Asset Management S.A. Buys 45,701 Shares of Henry Schein, Inc. $HSIC - MarketBeat

Mar 29, 2026

Henry Schein stock drops 2.18% as company recognized among World’s Most Ethical Companies - Traders Union

Mar 29, 2026

Henry Schein Inc Stock: A Steady Force in Dental and Medical Distribution for Long-Term Investors - AD HOC NEWS

Mar 29, 2026

Mar 28, 2026

Henry Schein (HSIC) price target increased by 12.37% to 90.80 - MSN

Mar 28, 2026

Mar 27, 2026

Henry Schein stock hits 52-week highhere's why - msn.com

Mar 27, 2026

Henry Schein Inc. stock underperforms Friday when compared to competitors - MarketWatch

Mar 27, 2026

Vanguard Reports 0 Shares in Henry Schein After Realignment (NASDAQ: HSIC) - Stock Titan

Mar 27, 2026

Henry Schein One Drives Growth with Cloud-Based Dental Solutions and AI Integration - Bitget

Mar 27, 2026

Mar 26, 2026

Henry Schein (HSIC) Down 9.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Mar 26, 2026

Should You Keep Henry Schein Shares in Your Investment Portfolio at This Time? - Bitget

Mar 26, 2026

Should You Retain Henry Schein Stock in Your Portfolio for Now? - Yahoo Finance

Mar 26, 2026

How Investors May Respond To Henry Schein (HSIC) Strong Q4 Specialty Products-Driven Margin Expansion - Sahm

Mar 26, 2026

Henry Schein (HSIC) Goldman Sachs 45th Annual Global Healthcare Conference Summary - Quartr

Mar 26, 2026

Mar 25, 2026

How Surging Global Specialty Sales At Henry Schein (HSIC) Have Changed Its Investment Story - Yahoo Finance

Mar 25, 2026